ALD2510 / Alderaan Biotechnology - LARVOL DELTA

Selective depletion of regulatory T cells by ALD2510, a novel IL-2-sparing anti-CD25 antibody, synergizes with PD-1 blockade in breast and gynecologic cancers (AACR 2023) - "Yet, subsets of Tregs remain to be determined in breast & gynecologic cancers, in order to: (i) evaluate the role of eTregs in resistances to PD-1 blockade, (ii) identify the most selective target for eTregs depletion tailored to tumors context and combination strategy. We collected public single-cell RNA/TCR-sequencing data from primary tumors and metastases of Triple-Negative Breast Cancer patients (TNBC, N = 28) biopsied before and after αPD-1 (pembrolizumab). This study supports clinical evaluation of CD25high effector Tregs depletion by ALD2510 in patients with breast or gynecologic cancers resistant to PD-1 blockade."

IO biomarker • Breast Cancer • Gynecologic Cancers • Oncology • Solid Tumor • Triple Negative Breast Cancer • CCR8 • CD34 • IL2

Preclinical development of ALD2510, a Next-Gen Fc-enhanced, TREG-selective and IL-2-sparing anti-CD25 antibody for the treatment of solid tumors (AACR 2023) - "Noteworthy, strong TREG depletion was confirmed while CD4+ or CD8+ T-cells were not impacted, confirming ALD2510 selectivity for TREGS while sparing TCONV. This makes ALD2510 a promising candidate for the treatment of solid tumors, in particular those where the presence of TREGS in the TME is associated with worse prognosis and/or resistance to CPI."

Preclinical • Oncology • Solid Tumor • CD4 • CD8 • IL2

ALD2510: Next Generation Fc-enhanced, TREG-selective and IL-2-sparing anti-CD25 antibody with promising potential for the treatment of gynecological cancers (SITC 2022) - "Conclusions ALD2510 is a next generation Fc-enhanced, T REG -selective and IL-2-sparing anti-CD25 mAb showing in vitro and in vivo efficacy , fully satisfactory safety and tolerability in NHP and excellent manufacturability. ALD2510 thus appears as a promising candidate for treatment of solid tumor patients, especially those suffering from gynecological malignancies, where highly immunosuppressive CD25 high T REGS were identified in the TME."

Gynecologic Cancers • Oncology • CD4 • CD8 • IL2

SELECTIVE TREG DEPLETION IN SOLID TUMORS WITH ALD2510, A NOVEL HUMANIZED CD25-SPECIFIC, IL-2 SPARING MONOCLONAL ANTIBODY. (SITC 2021) - "Importantly, Basiliximab, a CD25-specific IL-2 blocking antibody, although efficient at depleting Treg cells, did not impact tumor growth, thus demonstrating that the IL-2 sparing feature of ALD2510 is critical to elicit anti-tumour response in vivo. Conclusions This preclinical data package supports CD25 as a potent and selective Treg marker allowing Tregs depletion while sparing conventional T cells. In this context, ALD2510, a novel humanized CD25-specific and IL-2 sparing antibody presents all the required attributes for selective and efficient TIL-Tregs depletion, making it a promising drug candidate to treat a broad range of solid tumor patients."

IO biomarker • Oncology • Solid Tumor • CD34 • CD8 • IL2 • IL2RA